These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 30816799)

  • 1. Novel Antiatherosclerotic Therapies.
    Libby P; Everett BM
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):538-545. PubMed ID: 30816799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Ridker PM
    Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
    Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
    Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory therapies for cardiovascular disease.
    Ridker PM; Lüscher TF
    Eur Heart J; 2014 Jul; 35(27):1782-91. PubMed ID: 24864079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
    Grebe A; Hoss F; Latz E
    Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
    Ajala ON; Everett BM
    Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk.
    Mohammadnia N; Opstal TSJ; El Messaoudi S; Bax WA; Cornel JH
    Clin Ther; 2023 Nov; 45(11):1055-1059. PubMed ID: 37716836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
    Ridker PM; MacFadyen JG; Thuren T; Libby P
    Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
    Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
    Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new strategy for the treatment of atherothrombosis - inhibition of inflammation.
    Slíva J; Charalambous C; Bultas J; Karetová D
    Physiol Res; 2019 Nov; 68(Suppl 1):S17-S30. PubMed ID: 31755287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand?
    Rakocevic J; Dobric M; Borovic ML; Milutinovic K; Milenkovic S; Tomasevic M
    Rev Cardiovasc Med; 2023 Jan; 24(1):10. PubMed ID: 39076864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
    Ridker PM
    Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Anti-Atherosclerotic Therapies.
    Gluba-Brzózka A; Franczyk B; Rysz-Górzyńska M; Ławiński J; Rysz J
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?
    Ridker PM
    Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease.
    Zheng WC; Chan W; Dart A; Shaw JA
    Eur Heart J Cardiovasc Pharmacother; 2024 Jan; 10(1):53-67. PubMed ID: 37813820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.